Masimo Corp. (NASDAQ:MASI) hit a new 52-week high on Thursday . The company traded as high as $53.80 and last traded at $53.18, with a volume of 118,439 shares traded. The stock had previously closed at $52.67.

A number of equities research analysts recently weighed in on MASI shares. Raymond James Financial Inc. cut Masimo Corp. from a “strong-buy” rating to an “outperform” rating in a research note on Wednesday, June 1st. Wedbush upped their price objective on Masimo Corp. from $51.00 to $57.00 and gave the stock an “outperform” rating in a research note on Thursday, May 5th. Zacks Investment Research upgraded Masimo Corp. from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a research note on Friday, May 6th. Roth Capital upped their price objective on Masimo Corp. from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, May 5th. Finally, Piper Jaffray Cos. upgraded Masimo Corp. from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $43.00 to $52.00 in a research note on Thursday, May 5th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $50.80.

The stock’s 50-day moving average is $51.49 and its 200 day moving average is $43.18. The firm has a market cap of $2.57 billion and a P/E ratio of 30.92.

Masimo Corp. (NASDAQ:MASI) last posted its earnings results on Wednesday, May 4th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.10. The business had revenue of $171.20 million for the quarter, compared to analyst estimates of $165.25 million. During the same period last year, the business earned $0.41 EPS. Masimo Corp.’s revenue was up 10.8% compared to the same quarter last year. On average, equities research analysts predict that Masimo Corp. will post $1.83 earnings per share for the current fiscal year.

In other news, CAO Ramshorst David J. Van sold 5,000 shares of Masimo Corp. stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $52.50, for a total value of $262,500.00. Following the completion of the sale, the chief accounting officer now directly owns 3,000 shares of the company’s stock, valued at $157,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jon Coleman sold 4,000 shares of Masimo Corp. stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $44.00, for a total value of $176,000.00. Following the completion of the sale, the insider now directly owns 4,459 shares of the company’s stock, valued at $196,196. The disclosure for this sale can be found here.

Other large investors have recently modified their holdings of the company. Trexquant Investment LP purchased a new stake in shares of Masimo Corp. during the fourth quarter worth $1,009,000. Numeric Investors LLC purchased a new stake in shares of Masimo Corp. during the fourth quarter worth $1,050,000. Sawtooth Asset Management Inc. boosted its stake in shares of Masimo Corp. by 19,950.0% in the fourth quarter. Sawtooth Asset Management Inc. now owns 27,669 shares of the company’s stock worth $1,149,000 after buying an additional 27,531 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of Masimo Corp. by 160.1% in the fourth quarter. GSA Capital Partners LLP now owns 29,151 shares of the company’s stock worth $1,210,000 after buying an additional 17,944 shares during the last quarter. Finally, Globeflex Capital L P boosted its stake in shares of Masimo Corp. by 17.5% in the fourth quarter. Globeflex Capital L P now owns 34,900 shares of the company’s stock worth $1,449,000 after buying an additional 5,200 shares during the last quarter.

Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.